ARID1A and neoplasm: We find that 11.5% of all UBC harbor ARID1A pathogenic mutations, most of them truncating, and that multiple gene mutations can be found in some of the tumors/cell lines, supporting biallelic inactivation or intratumoral heterogeneity, as has been reported in other tumor types [44].